HIMS:NYSEHims & Hers Health, Inc. analysis

Hims & Hers is trading at $26.82, well above its DCF‑derived fair value of roughly $10, signaling a material overvaluation. The stock sits just under the 20‑day SMA (≈$25.9) and above the 50‑day SMA, while the MACD histogram remains positive, suggesting short‑term bullish momentum, yet the RSI hovers around 51, indicating a neutral stance. Volatility is extreme at ~85% over the past 30 days and beta exceeds 2.5, underscoring heightened price swings relative to the market. Fundamentally, revenue grew 3.8% YoY to $608 M and the company now projects $690 M for the next quarter, beating consensus, but operating margins are still deeply negative and debt‑to‑equity tops 250%, raising solvency concerns. The recent $350 M convertible‑note issuance provides liquidity for growth initiatives, but the combination of high leverage, thin profitability and an “Extreme Greed” market sentiment adds considerable downside risk.